Preclinical evaluation of the homo-aza-steroid ester 13β-hydroxy-13α-amino-13,17-seco-5α-androstan-17-oic-13, 17-lactam-p-bis(2-chloroethyl)aminophenoxy acetate for the treatment of malignant melanoma

Journal of B.U.ON.

Volumn 8, Issue 4, 2003, Pages 333-339

  Trafalis, D T P ^a,d   Camoutsis, Ch ^a,e   Karamanakos, P ^b   Arvanitis, A ^c   Tegou, E ^a   Ziras, N ^d   Athanassiou, A E ^d  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Nephrology Department   (Greece)

^d METAXA CANCER HOSPITAL   (Greece)

^e NONE   (Greece)

Author keywords

B16 melanoma; Dacarbazine; Homo aza steroid ester; Human cell lines; Melanoma

Indexed keywords

13BETA HYDROXY 13ALPHA AMINO 13,17 SECO 5ALPHA ANDROSTAN 17 OIC 13,17 LACTAM 4 BIS(2 CHLOROETHYL)AMINOPHENOXY ACETATE; ANTINEOPLASTIC AGENT; DACARBAZINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; LIVER MICROSOME; MALE; MELANOMA; MOUSE; NONHUMAN; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VOLUME;

EID: 2442659162     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Beddingfield FC. The melanoma epidemic: Res Ipsa Loquitur. Oncologist 2003; 8:459-465.
2. Hunckharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11:75-81.
3. Catsoulacos P, Politis D, Wampler GL. A new steroidal alkylating agent with improved activity in advanced murine leukemias. Cancer Chemother Pharmacol 1979; 3:67-70.
4. Catsoulacos P, Camoutsis C, Wampler GL. Effect of a Δ5homo-aza-steroidal ester in P388 and L1210 murine leukemias. Oncology 1982; 39:59-60.
5. Catsoulacos P. Activity of 3β-hydroxy-13α-amino-13,17-seco-5α-androstan-17-oic-13, 17-lactam p-bis (2-chloroethyl)aminophenoxy acetate (NSC-294859) on experimental tumor and leukemia systems. Oncology 1983; 40:290-292.
6. Catsoulacos P, Wampler GL. Activity of 3β-hydroxy-13α-amino-13, 17-seco-5α-androstan-17-oic- 13,17-lactam(p-bis(2-chloroethyl)amino)-phenyl)acetate (NSC-290205) in murine solid tumors. Oncology 1982; 39:109-112.
7. Catsoulacos P. Further studies on the anti-neoplastic activity of 3β-hydroxy-13α-amino-13,17-seco-5α -androstan-17-oic-13, 17-lactam(p-bis(2-chloroethyl)amino)-phenyl) acetate(NSC-290205). Cancer Lett 1984; 22:199-202.
8. Wall ME, Abernethy SG, Carroll JFI, Taylor DJ. The effects of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems. J Med Chem 1969; 12:810-818.
9. Wampler GL, Catsoulacos P. Antileukemic effect of homo-aza-steroidal-ester of [p-[bis(2-chloroethyl)amino]acetic acid. Cancer Treat Rep 1977; 61:37-41.
10. Catsoulacos P, Boutis L. Aza-steroids. Beckmann rearrangement of 3β-acetoxy-5α-androstan-17-one oxime acetate with boron fluoride. Alkylting agents. Chim Ther 1973; 8:215-217.
11. Arvanitis A, Trafalis D, Camoutsis C, Tegou E, Stavrianeas N. Effect of the steroidal lactam alkylating ester NSC-294859 on primary human melanoma cell lines. 20th World Congr Dermatol (Paris). Ann Dermatol Venereol 2002; 1(Suppl): 634.
12. Maron D, Ames BN. Revised methods for the salmonella mutagenicity test. Mutation Res 1983; 113: 173-215.
13. Voutsinas G, Kappas A, Demopoulos NA, Catsoulacos P. Mutagenic activity of the antitumor agent homo-aza-steroidal ester of p-N,N-bis(2-chloroethyl)aminophenoxy acetic acid (NSC-294859) in the salmonella microsome assay. Mutagenesis 1993; 8:431-435.
14. Finlay GJ, Wilson WR, Baguley BC. Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. Eur J Cancer Clin Oncol 1986; 22:655-662.
15. Alley MC, Scudiero DA, Monks PA et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48:589-601.
16. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel Res 1995; 34:91-109.
17. Corbett TH, Valeriote FA. Rodent models in experimental chemotherapy. In: Kallman RF (ed). The use of rodent tumors in experimental cancer therapy: Conclusions and recommendations. Pergamon, 1987, pp 233-247.
18. NCI Monograph 55. NIH Publication 1986, No 80, p 193.
19. Principles of laboratory animal care. NIH Publication 1985, No 85, p 23.
20. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 1998; 77:1-10.
21. Catsoulacos P, Politis D, Wampler GL. Antitumor activity of homo-aza-steroidal esters of [p-bis(2-chloroethyl) amino]phenyl]acetic acid [p-bis(2-chloroethyl)amino] phenyl] butyric acid. Cancer Chemother Pharmacol 1983; 10: 129-132.
22. Catsoulacos P, Catsoulacos D. Antitumor activity of homo-aza-steroidal esters of p-N, N-bis(2-chloroethyl) amino phenoxy acetic acid. Anticancer Res 1993; 13:1203-1208.
23. Catsoulacos P, Camoutsis C, Papageorgiou A, Adamiak-Margariti E. Cytostatic effect of homo-aza-steroidal esters in vivo and in vitro structure-activity relationships. Anticancer Res 1992; 12:1617-1620.
24. Dalmases P, Gomez-Belinchon JI, Bonet J-J, Giner-Sorolla A, Schmid FA. Antineoplastic agents. II. A nitrogen mustard derivative of N-methylated steroidal lactam. Eur J Med Chem 1983; 18: 541-543.
25. Dalmases P, Cervantes G, Quintana J, Bonet J-J. Antineo-plastic agents. V. Nitrogen mustards of systematically modified steroidal ring A lactams. Eur J Med Chem 1984; 19:465-467.
26. Kabara JJ, Holzschu DL, Catsoulacos P. Structure function activity of azasterols and nitrogen containing steroids. Lipids 1976; 11:7555-7562.
27. Ma D, Wamg G, Wang S, Kozikowski AP, Lewin NE, Blumberg PM. Synthesis and protein kinase C binding activity of benzolactam-V-7. Bioorg Med Chem Let 1999; 9:1371-1374.
28. Endo Y, Yokohama A. Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of 2-alkylated benzolactams. Bioorg Med Chem Let 2000; 10:63-66.
29. Endo Y, Shimazu M, Fukasawa H et al. Synthesis computer modeling and biological evaluation of novel protein kinase C agonists based on a 7-membered lactam moiety. Bioorg Med Chem Let 1999; 9:173-178.
30. Kokoschka EM, Spona J, Knobler R. Sex steroid hormone receptor analysis in malignant melanoma. Brit J Dermatol 1982; 107:54-59.
31. Rose C, Pedersen L, Mouridsen HT. Endocrine treatment with anti-estrogen, anti-androgen or progestagen of advanced malignant melanoma: three consecutive phase II trials. Eur J Cancer Clin Oncol 1985; 21:1171-1174.
32. Flowers JL, Seigler HF, McCarty KSSr, Konrath J, McCarty KSJr. Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. Arch Dermatol 1987; 123:764-765.
33. Lorea P, Decaestecker C, Goldschmidt D et al. Correlation between gender and cytomorphonuclear characteristics in human melanoma and in vitro evidence of sex steroid-induced modifications in the morphonuclear characteristics of three human melanoma cell lines. Melanoma Res 1997; 7:382-392.
34. Kawai S, Yahata N, Nishida S, Nagai K, Mizushima Y. Dehydroepiandrosterone inhibits B16 mouse melanoma cell growth by induction of differentiation. Anticancer Res 1995; 15:427-431.
35. Leclercq G, Devleeschouwer N, Pairas G, Camoutsis Ch, Catsoulacos P. Effect of an homo-aza-steroid on estrogen receptor. Meth Find Exptl Clin Pharmacol 1983; 5:365-367.
36. Papageorgiou A, Ivanov IG, Markov GG, Koliais SI, Boutis L, Catsoulacos P. Interaction of homo-aza-steroidal ester of [p-[bis-(2-chloroethyl)amino] acetic acid (ASE) with DNA of Ehrlich ascites tumor cells. FEBS Lett 1983; 153:194-198.
37. Shepherd RE, Huff K, McGuire WL. Brief communication: Estrogen receptor interaction with antitumor agent estradiol mustard. J Nat Cancer Inst 1974; 53:895-897.
38. Camoutsis C, Trafalis DTP. An overview on the antileukemic potential of D-homo-aza- and respective 17β-acetamido-steroidal alkylating esters. Invest New Drugs 2003; 21:47-54.
39. Catsoulacos P, Catsoulacos D. Conjugated systems of homo -aza-steroidal esters in cancer chemotherapy. Anticancer Res 1994; 14:2525-2528.
40. Catsoulakos P, Catsoulakos D. Hybrid anticancer compounds. Steroidal lactam esters of carboxylic derivative of N, N-bis (2-chloroethyl) aniline. Anticancer Res 1991; 11: 1773-1778.
41. Hayward IP, Parson PG. Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno)-imidazole-4-carboxamide in human melanoma cells. Aust J Exp Biol Med Sci 1984; 62:597-606.
42. Leo A, Panthananickal A, Hansch C, Theiss J, Shimkin M, Andrews AW. A comparison of mutagenic and carcinogenic activities of aniline mustards. J Med Chem 1981; 24:859-864.
43. Catsoulacos P, Papageorgiou A, Margariti E, Mourelatos D, Mioglou E. Comparison of current alkylating agents with a homo-aza-steroidal ester for antineoplastic activity. Oncology 1994; 51: 74-78.